See-thru value: Why HTAs must show true drug benefit
This article was originally published in SRA
News that the National Insitute for Health and Clinical Excellence in the UK is to be responsible for conducting the "full value assessment" in the country’s future value-based pricing or VBP system has again raised questions about the nature of "value" where medicines are concerned1,2.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.